The Menopause Society Annual Meeting

New research presented at TMS 2025 suggests menopause stage does not accelerate brain volume loss—age does. Study author discusses clinical implications for PCPs.

Analysis of 4 clinical trials, including 3 from the phase 3 OASIS development program, found treatment-emergent AEs comparable between elinzanetant and placebo.

TMS 2025: Wide variability in practice patterns suggests a need for standardized education across both specialties and provider types to ensure consistent quality of care.

TMS 2025: Machine learning uncovered 6 menopausal phenotypes, linking symptom patterns and metabolic risk and potential for personalized treatment strategies.

TMS 2025. University of Toronto professor Dr Marla Shapiro explains why perimenopause is unpredictable, including age of onset, duration, and symptoms.

If approved, the nonhormonal drug could offer an important new option for postmenopausal women seeking alternatives to hormone therapy.

Bayer's elinzanetant, a potential nonhormonal treatment for menopausal symptoms, awaits FDA approval after a 90-day review extension.

Pooled data from the OASIS clinical trial program showed consistent efficacy of elinzanetant across BMI and smoking history subgroups, highlighting its broad applicability.

JoAnn Pinkerton, MD, details the positive findings from the OASIS 1, 2, and 3 studies of elinzanetant and highlights next steps in research.